Final Study Results are Expected in First Half of 2023 TARRYTOWN, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today announced that… Read More..

Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 PRINCETON, N.J., Oct. 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of… Read More..

- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application - - Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the Treatment of X-Linked Recessive Ichthyosis - BASKING RIDGE, NJ, Oct. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc.… Read More..